Episode Details

Yellow card scheme, Don’t wait for someone else to report it https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions It is estimated that only 10% of serious reactions and between 2 and 4% of non-serious reactions are reported. Yellow card government site, just a click away https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting As of 23 November 2022, (UK) Pfizer/BioNTech, monovalent and bivalent 177,925 Yellow Cards have been reported AstraZeneca 246,866 have been reported Moderna, monovalent and bivalent 47,045 have been reported Novavax 52 reports Brand of vaccine was not specified 2,130 reports Total reports 474,018 Overall reporting rate Around 2 to 5 Yellow Cards per 1,000 doses administered In the 28 days Pfizer/BioNTech, + 2,499 reports AstraZeneca, + 228 Moderna, + 1,099 Novavax, + 15 Brand not specified, + 154 For all COVID-19 vaccines injection-site reactions (sore arm for example) generalised symptoms such as ‘flu-like’ illness headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, rapid heartbeat they may be reported more frequently in younger adults Overall, our advice remains that the benefits of the vaccines outweigh the risks in the majority of people. The benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects in the majority of patients. https://wchh.onlinelibrary.wiley.com/doi/pdf/10.1002/psb.1789 Google YT guidelines https://support.google.com/youtube/answer/9891785 Claims that an approved COVID-19 vaccine will cause death, infertility, miscarriage, autism, or contraction of other infectious diseases https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna 4.4 Special warnings and precautions for use Hypersensitivity and anaphylaxis Anaphylaxis has been reported in individuals who have received Spikevax. Close observation for at least 15 minutes is recommended following vaccination. Myocarditis and pericarditis There is an increased risk for myocarditis and pericarditis following vaccination with Spikevax. Few days, primarily occurred within 14 days, more often after the second dose, more often in younger males risk profile appears to be similar for the second and the third dose Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis. Vaccinated individuals should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis, such as (acute or persisting) chest pain, shortness of breath or palpitations following vaccination. Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition. Who can get a COVID-19 vaccine https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/ Everyone aged 5 (on or before 31 August 2022) and over can get a 1st and 2nd dose of the COVID-19 vaccine. People aged 16 and over, and some children aged 12 to 15, can also get a booster dose. Hypertension after COVID-19 vaccination https://pubmed.ncbi.nlm.nih.gov/34985455/ Italian research

Learn more about your ad choices. Visit megaphone.fm/adchoices